QPharma Announces Acquisition of Qforma
News Dec 29, 2015
QPharma has announced the acquisition of Qforma, Inc., a BelHealth Investment Partners (“BelHealth”) portfolio company. The Morris Plains-based firm offers an array of life sciences solutions that include healthcare analytics, predictive modeling, and product launch services.
For more than 20 years, QPharma has worked closely with pharmaceutical, medical device, and biotechnology manufacturers to validate their systems and facilities; plan their product launches; manage their pharmaceutical sample distribution; coordinate their state and federal transparency reporting; train their sales forces; and solve their regulatory compliance problems.
In recent years, the company has added new solutions that include Key Opinion Leader (KOL) identification, influence mapping, and analytics. From modest beginnings as a provider of computer system validation services, QPharma has steadily grown to become a leader in its industry.
“The purchase of Qforma is a natural progression of the incremental growth strategy that has served QPharma well in the past two decades,” said QPharma President and CEO Patrick Den Boer. “The outstanding technology platform and solution base they have built is a perfect complement to QPharma’s suite of business intelligence tools.”
“We are pleased to see this transaction come to fruition,” added Inder Tallur, Managing Director of BelHealth. “We believe this acquisition will enable QPharma to deliver outstanding value-added services, to the benefit of its growing roster of valued clients.”
To avoid name confusion, the Qforma brand will be phased out, and the company will continue to operate as QPharma. With the acquisition, QPharma will increase its headcount by 10 percent, with new sales, strategy, and technology personnel based at offices throughout the United States. The company expects to announce updates on its enhanced set of services in the coming months.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE